Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Cytokinetics Inc banner

Cytokinetics Inc
NASDAQ:CYTK

Watchlist Manager
Cytokinetics Inc Logo
Cytokinetics Inc
NASDAQ:CYTK
Watchlist
Price: 64.93 USD 2.48%
Market Cap: $7.9B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

CYTK Price Targets Summary
Cytokinetics Inc

Wall Street analysts forecast CYTK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYTK is 91.56 USD with a low forecast of 61.61 USD and a high forecast of 142.8 USD.

CYTK Lowest Forecast
Wall Street Target
61.61 USD
-5% Downside
CYTK Average Forecast
Wall Street Target
91.56 USD
41% Upside
CYTK Highest Forecast
Wall Street Target
142.8 USD
120% Upside
Lowest
Price Target
61.61 USD
5% Downside
Average
Price Target
91.56 USD
41% Upside
Highest
Price Target
142.8 USD
120% Upside
Cytokinetics Inc Competitors:
Price Targets
APA
APA Corp (US)
-4% Downside
WASH
Washington Trust Bancorp Inc
-4% Downside
GOSS
Gossamer Bio Inc
306% Upside
S
STG
Strip Tinning Holdings PLC
127% Upside
APA
APA Corp (US)
-4% Downside
WASH
Washington Trust Bancorp Inc
-4% Downside
GOSS
Gossamer Bio Inc
306% Upside
S
STG
Strip Tinning Holdings PLC
127% Upside

Revenue
Forecast

12% / Year
Past Growth
165% / Year
Estimated Growth
Estimates Accuracy
6%
Average Beat
12% / Year
Past Growth
165% / Year
Estimated Growth
Estimates Accuracy
6%
Average Beat

For the last 13 years the compound annual growth rate for Cytokinetics Inc's revenue is 12%. The projected CAGR for the next 4 years is 165%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-57%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-57%
Average Miss

What are analyst estimates?

See Also

Summary
CYTK intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYTK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYTK stock valuation using valuation multiples.
Wall Street Estimates
CYTK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYTK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CYTK's stock price target?
Price Target
91.56 USD

According to Wall Street analysts, the average 1-year price target for CYTK is 91.56 USD with a low forecast of 61.61 USD and a high forecast of 142.8 USD.

What is Cytokinetics Inc's Revenue forecast?
Projected CAGR
165%

For the last 13 years the compound annual growth rate for Cytokinetics Inc's revenue is 12%. The projected CAGR for the next 4 years is 165%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 316,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.